Anavex Life Sciences (AVXL) vs Cognition Therapeutics (CGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cognition Therapeutics (CGTX) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 58.1% versus a loss of 81.9%. Over five years, CGTX leads with a -93.5% price change compared with -97.0% for AVXL. Cognition Therapeutics is the larger company by market cap ($55.4 million vs $54.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | CGTX |
|---|---|---|
| Share price | $0.5915 | $0.5822 |
| Market cap | $54.83M | $55.37M |
| 1-day change | -11.39% | -3.06% |
| YTD return | -83.38% | -56.87% |
| 1-year return | -81.86% | -58.12% |
| 5-year return | -96.96% | -93.47% |
| EPS (TTM) | $-0.14 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-46.38M | $-23.49M |
| 52-week high | $5.36 | $1.81 |
| 52-week low | $0.59 | $0.55 |
| Distance from 52-week high | -88.96% | -67.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +471.97% |
| Average volume | 1.15M | 464.94K |
| Shares outstanding | 92.70M | 95.10M |
| Employees | 34 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGTX has outperformed AVXL by 23.7 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
AVXL vs CGTX FAQ
Which is bigger, Anavex Life Sciences or Cognition Therapeutics?
Cognition Therapeutics (CGTX) is larger, with a market capitalization of $55.37M compared with $54.83M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or CGTX?
CGTX returned -58.12% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Cognition Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.